Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Percheron Therapeutics ( (AU:PER) ) just unveiled an update.
Percheron Therapeutics Limited announced the results of its Annual General Meeting, where all resolutions were decided by a poll. Notably, the adoption of the 2025 Remuneration Report was supported by more than 75% of votes, leading to the withdrawal of the Conditional Spill Resolution. This outcome reflects strong shareholder support and suggests stability in the company’s governance, potentially influencing its strategic direction and investor confidence.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator, VISTA, which has completed a phase I clinical trial in patients with advanced cancer.
Average Trading Volume: 2,975,046
Technical Sentiment Signal: Sell
Current Market Cap: A$9.79M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.